Skip to main content

Clinical Trials Using Autologous Anti-CD19 CAR-expressing T Lymphocytes

Review the clinical trials studying autologous anti-cd19 car-expressing t lymphocytes on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-4 of 4

Genetically Engineered Cells (Anti-CD19 CAR-T Cell Therapy) and Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Refractory/Relapsed Aggressive Non-Hodgkin Lymphoma
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Status: Active
Location: University of California San Francisco, San Francisco, California
Genetically Engineered Cells (Anti-CD19 CAR-T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies, The PRODIGY Trial
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah